{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'from baseline 60 msec.', 'g. when a blind is broken due to', 'g.', 'when a blind is broken due to', 'safety concerns (see', 'safety concerns (see', 'Section 3.7.2). If a patient is', 'Section 3.7.2). If a patient is', 'unblinded by mistake, they', 'unblinded by mistake, they', 'should not be withdrawn.', 'should not be withdrawn.', 'h.', 'if the investigator or the', 'h.', 'if the investigator or the', 'sponsor determines that the', 'sponsor determines that the', 'patient is not in compliance', 'patient is not in compliance', 'with the study protocol, the', 'with the study protocol, the', 'investigator and the sponsor', 'investigator and the sponsor', 'should determine whether the', 'should determine whether the', 'patient should be withdrawn', 'patient should be withdrawn', 'from the study (Section 5.4).', 'from the study (Section 5.4).', 'Section 5.2 Restrictions', 'While patients receiving strong CYP2D6', 'While patients receiving strong CYP2D6', 'Clarificatio', 'inhibitors (such as paroxetine, fluoxetine,', 'inhibitors such as paroxetine, fluoxetine,', 'n on the use', 'and bupropion) at baseline may be enrolled', 'and bupropion at baseline may be enrolled', 'of quinidine', 'into this study, the addition or removal of', 'into this study, the addition or removal of', 'and', 'strong CYP2D6 inhibitors during treatment', 'strong CYP2D6 inhibitors during treatment', 'terbinafine', 'is discouraged as this would have an effect', 'is discouraged as this would have an effect', 'as', 'on exposure to active circulating drug. If the', 'on exposure to active circulating drug. If the', 'prohibited.', 'addition or removal of a strong CYP2D6', 'addition or removal of a strong CYP2D6', 'inhibitor is required from a clinical', 'inhibitor is required from a clinical', 'perspective, the medical monitor should be', 'perspective, the medical monitor should be', 'contacted so an appropriate change in IMP', 'contacted so an appropriate change in IMP', 'can be made. The use of quinidine and', 'can be made. The use of quinidine and', 'terbinafine are prohibited (see Appendix A,', 'terbinafine are prohibited (see Appendix A,', 'Table 8).', 'Table 8).', 'Section 5.5 Dose Reduction and Temporary IMP Discontinuation', 'Suspension of study medication for up to 1', 'Suspension of study medication for up to 1', 'Blood', 'one week, if warranted for patient safety, is', 'week, if warranted for patient safety, is', 'sampling', 'allowed. If the patient restarts study', 'allowed. If the patient restarts study', 'quantity', 'medication within 7 days of suspension, the', 'medication within 7 days of suspension, the', 'specificatio', 'full dose of TEV-50717 may be resumed', 'full dose of TEV-50717 may be resumed', 'n.', 'without titration. Suspensions of study', 'without titration. Suspensions of study', 'medication for adverse events must be', 'medication for adverse events must be', 'reviewed with the medical monitor before', 'reviewed with the medical monitor before', \"therapy is restarted. If a subject's serum\", \"therapy is restarted. If a subject's serum\", 'potassium or magnesium fallswere tested', 'potassium or magnesium were tested and', 'and found to be below the lower limit of', 'found to be below the lower limit of normal,', 'normal, IMP must be suspended. The', 'IMP must be suspended. The medical', 'Medical Monitor must be contacted to', 'monitor must be contacted to determine the', '183']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'determine the appropriate investigation and', 'appropriate investigation and treatment.', 'treatment. SD 809TEV-50717 may only be', 'TEV-50717 may only be restarted once', 'restarted once serum potassium or', 'serum potassium or magnesium have', 'magnesium have normalized. Similarly,', 'normalized.', 'suspensions for more than 7 days must be', 'reviewed by the medical monitor to', 'determine if there is adequate time for', 'patients to be reiterated and complete', 'study evaluations.', 'Table 3: Blood Volumes', 'Type of samples', 'Volu', 'Total', 'Total', 'Type of samples', 'Volu', 'Total', 'Total', 'Blood', 'me', 'numbe', 'volu', 'me', 'numbe', 'volu', 'sampling', 'per', 'r of', 'me', 'per', 'r of', 'me', 'quantity', 'sampl', 'sample', 'samp', 'sample', 'specificatio', 'e', 'S', 'le', 'S', 'n.', 'Clinical', '10', '2', '20', 'Clinical laboratory', '10', '2', '20', 'laboratory', 'mL', 'mL', '(ch mistry/hemat', 'mL', 'mL', '(chemistry/hemato', 'ology)', 'logy)', 'Pharmacokinetic', '5 mL', '1 time', '10', 'Pharmacokinetic', '5 mL', '1 time', '10', 'point', 'mL', 'point', 'mL', '(week', '(week', '12) X', '12) X', 'samp', '2 samp', 'les', 'les', 'CYP2D6', '3 mL', '1', '3 mL', 'CYP2D6', '53', '1', '53', 'genotyping', 'genotyping', 'mL', 'mL', 'Optional', '2 mL', '1', '2 mL', 'Optional', '2 mL', '1', '2 mL', 'pharmacogenetic', 'pharmacogenetic', 'sample', 'sample', 'Total', '35', 'Total', '35', 'mL', 'mL', 'CYP2D6=cytochrome P450 2D6.', 'CYP2D6=cytochrome P450 2D6.', 'Note: beta human chorionic gonadotropin', 'Note: beta human chorionic gonadotropin', 'testing (in females who are postmenarchal', 'testing (in females who are postmenarchal', 'or >12 years of age) is included in the', 'or >12 years of age) is included in the', 'clinical laboratory sample.', 'clinical laboratory sample.', 'Section 7.1.5.3.1 Investigator Responsibility', 'To satisfy regulatory requirements, all', 'To satisfy regulatory requirements, all', 'Clarificatio', 'serious adverse events that occur during the', 'serious adverse events that occur during the', 'n on the', 'study, regardless of judged relationship to', 'study, regardless of judged relationship to', 'expectation', 'administration of the IMP, must be reported', 'administration of the IMP, must be reported', 'of reporting', '184']\n\n###\n\n", "completion": "END"}